Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - BOOK LB - 1. AU - National Institute for Health and Care Excellence TI - Epoetin Alfa, Epoetin Beta and Darbepoetin Alfa for Cancer Treatment-Induced Anaemia CY - London PB - NICE PY - 2008 ER - TY - JOUR LB - 2. AU - Wilson, J AU - Yao, GL AU - Raftery, J AU - Bohlius, J AU - Brunskill, S AU - Sandercock, J TI - A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment J2 - Health Technol Assess PY - 2007 VL - 11 IS - 13 UR - http://dx.doi.org/10.3310/hta11130 ER - TY - JOUR LB - 3. AU - Schrijvers, D AU - De Samblanx, H AU - Roila, F TI - Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use J2 - Ann Oncol PY - 2010 VL - 21 SP - v244 EP - v247 UR - http://dx.doi.org/10.1093/annonc/mdq202 ER - TY - JOUR LB - 4. AU - Mercadante, S AU - Gebbia, V AU - Marrazzo, A AU - Filosto, S TI - Anaemia in cancer: pathophysiology and treatment J2 - Cancer Treat Rev PY - 2000 VL - 26 SP - 303 EP - 311 UR - http://dx.doi.org/10.1053/ctrv.2000.0181 ER - TY - JOUR LB - 5. AU - Schrijvers, D AU - Roila, F AU - Esmo Guidelines Working Group TI - Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use J2 - Ann Oncol PY - 2009 VL - 20 IS - Suppl. 4 SP - 159 EP - 161 ER - TY - JOUR LB - 6. AU - Groopman, JE AU - Itri, LM TI - Chemotherapy-induced anemia in adults: incidence and treatment J2 - J Natl Cancer Inst PY - 1999 VL - 91 SP - 1616 EP - 1634 UR - http://dx.doi.org/10.1093/jnci/91.19.1616 ER - TY - JOUR LB - 7. AU - Bohlius, J AU - Schmidlin, K AU - Brillant, C AU - Schwarzer, G AU - Trelle, S AU - Seidenfeld, J TI - Erythropoietin or darbepoetin for patients with cancer – meta-analysis based on individual patient data J2 - Cochrane Database Syst Rev PY - 2009 VL - 3 SP - CD007303 UR - http://dx.doi.org/10.1002/14651858.cd007303.pub2 ER - TY - JOUR LB - 8. AU - Vaupel, P AU - Mayer, A TI - Hypoxia and anemia: effects on tumour biology and treatment resistance J2 - Transfus Clin Biol PY - 2005 VL - 12 SP - 5 EP - 10 UR - http://dx.doi.org/10.1016/j.tracli.2004.11.005 ER - TY - JOUR LB - 9. AU - Schrijvers, D AU - Highley, M AU - De Bruyn, E AU - Van Oosterom, A AU - Vermorken, J TI - Role of red blood cells in pharmacokinetics of chemotherapeutic agents J2 - Anticancer Drugs PY - 1999 VL - 10 SP - 147 EP - 153 UR - http://dx.doi.org/10.1097/00001813-199902000-00002 ER - TY - JOUR LB - 10. AU - Hockel, M AU - Knoop, C AU - Schlenger, K AU - Vorndran, B AU - Baussmann, E AU - Mitze, M TI - Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix J2 - Radiother Oncol PY - 1993 VL - 26 SP - 45 EP - 50 UR - http://dx.doi.org/10.1016/0167-8140(93)90025-4 ER - TY - JOUR LB - 11. AU - Tonia, T AU - Mettler, A AU - Robert, N AU - Schwarzer, G AU - Seidenfeld, J AU - Weingart, O TI - Erythropoietin or darbepoetin for patients with cancer J2 - Cochrane Database Syst Rev PY - 2012 VL - 12 SP - CD003407 UR - http://dx.doi.org/10.1002/14651858.cd003407.pub5 ER - TY - JOUR LB - 12. AU - Knocke, TH AU - Weitmann, HD AU - Feldmann, HJ AU - Selzer, E AU - Potter, R TI - Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix J2 - Radiother Oncol PY - 1999 VL - 18 SP - 156 EP - 169 UR - http://dx.doi.org/10.1016/s0167-8140(99)00139-5 ER - TY - JOUR LB - 13. AU - Vaupel, P AU - Thews, O AU - Mayer, A AU - Hockel, S AU - Hockel, M TI - Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? J2 - Strahlenther Onkol PY - 2002 VL - 178 SP - 727 EP - 731 UR - http://dx.doi.org/10.1007/s00066-002-1081-x ER - TY - JOUR LB - 14. AU - Leyland-Jones, B TI - Breast cancer trial with erythropoietin terminated unexpectedly J2 - Lancet PY - 2003 VL - 4 SP - 459 EP - 460 UR - http://dx.doi.org/10.1016/S1470-2045(03)01163-X ER - TY - JOUR LB - 15. AU - Henke, M AU - Laszig, R AU - Rube, C AU - Schafer, U AU - Haase, KD AU - Schilcher, B TI - Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial J2 - Lancet PY - 2003 VL - 362 SP - 1255 EP - 1260 UR - http://dx.doi.org/10.1016/S0140-6736(03)14567-9 ER - TY - JOUR LB - 16. AU - Smith, RE, Jr AU - Aapro, MS AU - Ludwig, H AU - Pinter, T AU - Smakal, M AU - Ciuleanu, TE TI - Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study J2 - J Clin Oncol PY - 2008 VL - 26 SP - 1040 EP - 1050 UR - http://dx.doi.org/10.1200/JCO.2007.14.2885 ER - TY - JOUR LB - 17. AU - Hedenus, M AU - Adriansson, M AU - San Miguel, J AU - Kramer, MH AU - Schipperus, MR AU - Juvonen, E TI - Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study J2 - Br J Haematol PY - 2003 VL - 122 SP - 394 EP - 403 UR - http://dx.doi.org/10.1046/j.1365-2141.2003.04448.x ER - TY - JOUR LB - 18. AU - Overgaard, J AU - Hoff, C AU - Sand Hansen, H AU - Specht, L AU - Overgaard, M AU - Grau, C TI - Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) – the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial J2 - Eur J Cancer Suppl PY - 2007 VL - 5 SP - 6LB ER - TY - JOUR LB - 19. AU - Wright, JR AU - Ung, YC AU - Julian, JA AU - Pritchard, KI AU - Whelan, TJ AU - Smith, C TI - Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia J2 - J Clin Oncol PY - 2007 VL - 25 SP - 1027 EP - 1032 UR - http://dx.doi.org/10.1200/JCO.2006.07.1514 ER - TY - JOUR LB - 20. AU - Goss, G AU - Feld, R AU - Bezjak, A AU - Perry, G AU - Melosky, Y AU - Smith, C TI - Impact of maintaining Hb with epoetin alfa on time to progression (TTP), overall survival (OS), quality of life (QOL) and transfusion reduction in limited disease SCLC patients J2 - Lung Cancer PY - 2005 VL - 49 SP - S53 UR - http://dx.doi.org/10.1016/S0169-5002(05)80288-0 ER - TY - JOUR LB - 21. AU - McBroom, JW AU - Acs, G AU - Rose, GS AU - Krivak, TC AU - Mohyeldin, A AU - Verma, A TI - Erythropoeitin receptor function and expression in epithelial ovarian carcinoma J2 - Gynecol Oncol PY - 2005 VL - 99 SP - 571 EP - 577 UR - http://dx.doi.org/10.1016/j.ygyno.2005.06.038 ER - TY - JOUR LB - 22. AU - Arcasoy, MO AU - Jiang, X AU - Haroon, ZA TI - Expression of erythropoietin receptor splice variants in human cancer J2 - Biochem Biophys Res Comm PY - 2003 VL - 307 SP - 999 EP - 1007 UR - http://dx.doi.org/10.1016/S0006-291X(03)01303-2 ER - TY - JOUR LB - 23. AU - Arcasoy, MO AU - Amin, K AU - Vollmer, RT AU - Jiang, X AU - Demark-Wahnefried, W AU - Haroon, ZA TI - Erythropoietin and erythropoietin receptor expression in human prostate cancer J2 - Mod Pathol PY - 2005 VL - 18 SP - 421 EP - 430 UR - http://dx.doi.org/10.1038/modpathol.3800288 ER - TY - JOUR LB - 24. AU - Dagnon, K AU - Pacary, E AU - Commo, F AU - Antoine, M AU - Bernaudin, M AU - Bernaudin, JF TI - Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas J2 - Clin Cancer Res PY - 2005 VL - 11 SP - 993 EP - 999 ER - TY - JOUR LB - 25. AU - Leo, C AU - Horn, LC AU - Rauscher, C AU - Hentschel, B AU - Liebmann, A AU - Hildebrandt, G TI - Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis J2 - Clin Cancer Res PY - 2006 VL - 12 SP - 6894 EP - 6900 UR - http://dx.doi.org/10.1158/1078-0432.CCR-06-1285 ER - TY - JOUR LB - 26. AU - Feldman, L AU - Wang, Y AU - Rhim, JS AU - Bhattacharya, N AU - Loda, M AU - Sytkowski, AJ TI - Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells J2 - Prostate PY - 2006 VL - 66 SP - 135 EP - 145 UR - http://dx.doi.org/10.1002/pros.20310 ER - TY - JOUR LB - 27. AU - Yasuda, Y AU - Fujita, Y AU - Matsuo, T AU - Koinuma, S AU - Hara, S AU - Tazaki, A TI - Erythropoietin regulates tumour growth of human malignancies J2 - Carcinogenesis PY - 2003 VL - 24 SP - 1021 EP - 1029 UR - http://dx.doi.org/10.1093/carcin/bgg060 ER - TY - JOUR LB - 28. AU - Mohyeldin, A AU - Lu, H AU - Dalgard, C AU - Lai, SY AU - Cohen, N AU - Acs, G TI - Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma J2 - Neoplasia PY - 2005 VL - 7 SP - 537 EP - 543 UR - http://dx.doi.org/10.1593/neo.04685 ER - TY - JOUR LB - 29. AU - Henke, M AU - Mattern, D AU - Pepe, M AU - Bezay, C AU - Weissenberger, C AU - Werner, M TI - Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J2 - J Clin Oncol PY - 2006 VL - 24 SP - 4708 EP - 4713 UR - http://dx.doi.org/10.1200/JCO.2006.06.2737 ER - TY - JOUR LB - 30. AU - Jelkmann, W AU - Bohlius, J AU - Hallek, M AU - Sytkowski, AJ TI - The erythropoietin receptor in normal and cancer tissues J2 - Crit Rev Oncol Hematol PY - 2008 VL - 67 SP - 39 EP - 61 UR - http://dx.doi.org/10.1016/j.critrevonc.2008.03.006 ER - TY - JOUR LB - 31. AU - Machtay, M AU - Pajak, TF AU - Suntharalingam, M AU - Shenouda, G AU - Hershock, D AU - Stripp, DC TI - Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03) J2 - Int J Radiat Oncol Biol Phys PY - 2007 VL - 69 SP - 1008 EP - 1017 UR - http://dx.doi.org/10.1016/j.ijrobp.2007.04.063 ER - TY - JOUR LB - 32. AU - Chang, J AU - Couture, F AU - Young, S AU - McWatters, KL AU - Lau, CY TI - Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy J2 - J Clin Oncol PY - 2005 VL - 23 SP - 2597 EP - 2605 UR - http://dx.doi.org/10.1200/JCO.2004.12.027 ER - TY - JOUR LB - 33. AU - Moebus, V AU - Lueck, H AU - Thomssen, C AU - Harbeck, N AU - Nitz, U AU - Kreienberg, R TI - The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO Phase III study (ETC trial) J2 - J Clin Oncol PY - 2007 VL - 25 IS - 18 Suppl. SP - 569 ER - TY - JOUR LB - 34. AU - Schrijvers, D TI - Management of anemia in cancer patients: transfusions J2 - Oncologist PY - 2011 VL - 16 IS - Suppl. 3 SP - 12 EP - 18 UR - http://dx.doi.org/10.1634/theoncologist.2011-S3-12 ER - TY - BOOK LB - 35. AU - Janssen-Cilag Ltd TI - Summary Product Characteristics: Eprex 40,000 IU/ml Solution for Injection in Pre-Filled Syringe CY - High Wycombe PB - Janssen-Cilag PY - 2012 ER - TY - BOOK LB - 36. AU - Sandoz Ltd TI - Summary of Product Characteristics: Binocrit Solution for Injection in a Pre-Filled Syringe CY - Camberley PB - Sandoz Ltd PY - 2012 ER - TY - BOOK LB - 37. AU - Hospira UK Ltd. TI - Summary of Product Characteristics: Retacrit Solution for Injection in Pre Filled Syringe CY - Leamington Spa PB - Hospira UK Ltd PY - 2012 ER - TY - BOOK LB - 38. AU - Roche Products Ltd TI - Summary of Product Characteristics: Neorecormon Solution for Injection in Pre-Filled Syringe CY - Welwyn Garden City PB - Roche Products Ltd PY - 2012 ER - TY - BOOK LB - 39. AU - Teva Pharmaceuticals Ltd TI - Summary of Product Characteristics: Eporatio 1,000 IU/0.5 ml Solution for Injection in Pre-Filled Syringe CY - Harlow PB - Teva Pharmaceuticals Ltd PY - 2012 ER - TY - BOOK LB - 40. AU - Amgen Inc TI - Summary of Product Characteristics: Aranesp PFS CY - Cambridge PB - Amgen Inc PY - 2012 ER - TY - JOUR LB - 41. AU - Bokemeyer, C AU - Aapro, MS AU - Courdi, A AU - Foubert, J AU - Link, H AU - Österborg, A TI - EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update J2 - Eur J Cancer PY - 2007 VL - 43 SP - 258 EP - 270 UR - http://dx.doi.org/10.1016/j.ejca.2006.10.014 ER - TY - JOUR LB - 42. AU - Rizzo, JD AU - Brouwers, M AU - Hurley, P AU - Seidenfeld, J AU - Arcasoy, MO AU - Spicak, JL TI - American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer J2 - J Clin Oncol PY - 2010 VL - 28 SP - 4996 EP - 5010 UR - http://dx.doi.org/10.1200/JCO.2010.29.2201 ER - TY - BOOK LB - 43. AU - British Columbia Cancer Agency TI - BCCA Protocol Summary Guidelines for the Use of Erythropoiesis-Stimulating Agents (ESAs) in Patients with Cancer CY - Vancouver, BC PB - British Columbia Cancer Agency PY - 2012 ER - TY - JOUR LB - 44. AU - Moher, D AU - Liberati, A AU - Tetzlaff, J AU - Altman, DG AU - PRISMA Group TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J2 - BMJ PY - 2009 VL - 339 SP - b2535 UR - http://dx.doi.org/10.1136/bmj.b2535 ER - TY - JOUR LB - 45. AU - Bohlius, J AU - Langensiepen, S AU - Schwarzer, G AU - Seidenfeld, J AU - Piper, M AU - Bennett, C TI - Erythropoietin for patients with malignant disease J2 - Cochrane Database Syst Rev PY - 2004 VL - 3 SP - CD00340 UR - http://dx.doi.org/10.1002/14651858.cd003407.pub2 ER - TY - BOOK LB - 46. AU - NICE TI - Final Scope: Anaemia (Cancer-Treatment Induced) – Erythropoiesis-Stimulating Agents (Epoetin and Darbepoetin) CY - London PB - NICE PY - 2014 ER - TY - CONF LB - 47. AU - Bohlius, J AU - Schmidlin, K AU - Brillant, C AU - Schwarzer, G AU - Trelle, S AU - Seidenfeld, J TI - Mortality in Cancer Patients Receiving Recombinant Human Erythropoiesis-Stimulating Agents: Individual Patient Data Meta-Analysis Based on Randomized Trials T2 - 8th International Luebeck Conference Pathophysiology and Pharmacology of Erythropoietin and other Hemopoietic Growth Factors DA - 2009 CY - Luebeck, Germany ER - TY - JOUR LB - 48. AU - Tjulandin, SA AU - Bias, P AU - Elsasser, R AU - Gertz, B AU - Kohler, E AU - Buchner, A TI - Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial J2 - Arch Drug Inf PY - 2010 VL - 3 SP - 45 EP - 53 UR - http://dx.doi.org/10.1111/j.1753-5174.2010.00030.x ER - TY - JOUR LB - 49. AU - Parmar, MK AU - Torri, V AU - Stewart, L TI - Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints J2 - Stat Med PY - 1998 VL - 17 SP - 2815 EP - 2834 UR - http://dx.doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 ER - TY - JOUR LB - 50. AU - Kotasek, D AU - Steger, G AU - Faught, W AU - Underhill, C AU - Poulsen, E AU - Colowick, AB TI - Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study J2 - Eur J Cancer PY - 2003 VL - 39 SP - 2026 EP - 2034 UR - http://dx.doi.org/10.1016/S0959-8049(03)00456-8 ER - TY - JOUR LB - 51. AU - ten Bokkel Huinink, WW AU - de Swart, CA AU - van Toorn, DW AU - Morack, G AU - Breed, WP AU - Hillen, HF TI - Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy J2 - Med Oncol PY - 1998 VL - 15 SP - 174 EP - 182 UR - http://dx.doi.org/10.1007/BF02821936 ER - TY - JOUR LB - 52. AU - Thatcher, N AU - De Campos, ES AU - Bell, DR AU - Steward, WP AU - Varghese, G AU - Morant, R TI - Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer J2 - Br J Cancer PY - 1999 VL - 80 SP - 396 EP - 402 UR - http://dx.doi.org/10.1038/sj.bjc.6690369 ER - TY - JOUR LB - 53. AU - Hedenus, M AU - Hansen, S AU - Taylor, K AU - Arthur, C AU - Emmerich, B AU - Dewey, C TI - Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies J2 - Br J Haematol PY - 2002 VL - 119 SP - 79 EP - 86 UR - http://dx.doi.org/10.1046/j.1365-2141.2002.03774.x ER - TY - BOOK LB - 54. AU - Higgins, JPT AU - Green, S TI - Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011] PB - The Cochrane Collaboration PY - 2011 ER - TY - ELEC LB - 55. AU - Dias, S AU - Welton, NJ AU - Sutton, AJ AU - Ades, AE TI - NICE DSU Technical Support Document 1: Introduction to evidence Synthesis for Decision Making. UR - www.nicedsu.org.uk M1 - 31 August 2015 ER - TY - JOUR LB - 56. AU - Egger, M AU - Smith, GD AU - Schneider, M AU - Minder, C TI - Bias in meta-analysis detected by a simple, graphical test J2 - BMJ PY - 1997 VL - 315 SP - 629 EP - 634 UR - http://dx.doi.org/10.1136/bmj.315.7109.629 ER - TY - JOUR LB - 57. AU - Harbord, RM AU - Egger, M AU - Sterne, JA TI - A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints J2 - Stat Med PY - 2006 VL - 25 SP - 3443 EP - 3457 UR - http://dx.doi.org/10.1002/sim.2380 ER - TY - JOUR LB - 58. AU - Henry, DH AU - Brooks, BJ, Jr AU - Case, DC, Jr AU - Fishkin, E AU - Jacobson, R AU - Keller, AM TI - Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy J2 - Canc J Sci Am PY - 1995 VL - 1 SP - 252 EP - 260 ER - TY - JOUR LB - 59. AU - Abels, RI AU - Larholt, KM AU - Krantz, KD AU - Bryant, EC TI - Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer J2 - Oncologist PY - 1996 VL - 1 SP - 140 EP - 150 ER - TY - JOUR LB - 60. AU - Patrick, DL AU - Gagnon, DD AU - Zagari, MJ AU - Mathijs, R AU - Sweetenham, J AU - Epoetin Alfa Study Group TI - Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa J2 - Eur J Cancer PY - 2003 VL - 39 SP - 335 EP - 345 UR - http://dx.doi.org/10.1016/S0959-8049(02)00628-7 ER - TY - JOUR LB - 61. AU - Wagner, LM AU - Billups, CA AU - Furman, WL AU - Rao, BN AU - Santana, VM TI - Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial J2 - J Clin Oncol PY - 2004 VL - 22 SP - 1886 EP - 1893 UR - http://dx.doi.org/10.1200/JCO.2004.01.002 ER - TY - JOUR LB - 62. AU - Moebus, V AU - Jackisch, C AU - Schneeweiss, A AU - Huober, J AU - Lueck, HJ AU - du Bois, A TI - Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial J2 - J Natl Cancer Inst PY - 2013 VL - 105 SP - 1018 EP - 1026 UR - http://dx.doi.org/10.1093/jnci/djt145 ER - TY - JOUR LB - 63. AU - Abels, R TI - Erythropoietin for anaemia in cancer patients J2 - Eur J Cancer PY - 1993 VL - 29A IS - Suppl. 2 SP - S2 EP - S8 UR - http://dx.doi.org/10.1016/S0959-8049(05)80281-3 ER - TY - JOUR LB - 64. AU - Aravantinos, G AU - Linardou, H AU - Makridaki, D AU - Laiou, E AU - Zafiropoulos, A AU - Janninis, J TI - Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: a single-centre randomised study J2 - J BUON PY - 2003 VL - 8 SP - 127 EP - 132 ER - TY - JOUR LB - 65. AU - Boogaerts, M AU - Coiffier, B AU - Kainz, C TI - Impact of epoetin beta on quality of life in patients with malignant disease J2 - Br J Cancer PY - 2003 VL - 88 SP - 988 EP - 995 UR - http://dx.doi.org/10.1038/sj.bjc.6600801 ER - TY - JOUR LB - 66. AU - Dammacco, F AU - Castoldi, G AU - Rodjer, S TI - Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma J2 - Br J Haematol PY - 2001 VL - 113 SP - 172 EP - 179 UR - http://dx.doi.org/10.1046/j.1365-2141.2001.02715.x ER - TY - JOUR LB - 67. AU - Del Mastro, L AU - Venturini, M AU - Lionetto, R AU - Garrone, O AU - Melioli, G AU - Pasquetti, W TI - Randomized Phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia J2 - J Clin Oncol PY - 1997 VL - 15 SP - 2715 EP - 2721 ER - TY - JOUR LB - 68. AU - Dunphy, FR AU - Harrison, BR AU - Dunleavy, TL AU - Rodriguez, JJ AU - Hilton, JG AU - Boyd, JH TI - Erythropoietin reduces anemia and transfusions: a randomized trial with or without erythropoietin during chemotherapy J2 - Cancer PY - 1999 VL - 86 SP - 1362 EP - 1367 UR - http://dx.doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1362::AID-CNCR36>3.0.CO;2-T ER - TY - JOUR LB - 69. AU - Kurz, C AU - Marth, C AU - Windbichler, G AU - Lahousen, M AU - Medl, M AU - Vavra, N TI - Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study J2 - Gynecol Oncol PY - 1997 VL - 65 SP - 461 EP - 466 UR - http://dx.doi.org/10.1006/gyno.1997.4675 ER - TY - JOUR LB - 70. AU - Littlewood, TJ AU - Bajetta, E AU - Nortier, JW AU - Vercammen, E AU - Rapoport, B AU - Epoetin Alfa Study Group TI - Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J2 - J Clin Oncol PY - 2001 VL - 19 SP - 2865 EP - 2874 ER - TY - JOUR LB - 71. AU - Österborg, A AU - Brandberg, Y AU - Molostova, V AU - Iosava, G AU - Abdulkadyrov, K AU - Hedenus, M TI - Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies J2 - J Clin Oncol PY - 2002 VL - 20 SP - 2486 EP - 2494 UR - http://dx.doi.org/10.1200/JCO.2002.08.131 ER - TY - JOUR LB - 72. AU - Silvestris, F AU - Romito, A AU - Fanelli, P AU - Vacca, A AU - Dammacco, F TI - Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma J2 - Ann Hematol PY - 1995 VL - 70 SP - 313 EP - 318 UR - http://dx.doi.org/10.1007/BF01696618 ER - TY - JOUR LB - 73. AU - Vansteenkiste, J AU - Pirker, R AU - Massuti, B AU - Barata, F AU - Font, A AU - Fiegl, M TI - Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J2 - J Natl Cancer Inst PY - 2002 VL - 94 SP - 1211 EP - 1220 UR - http://dx.doi.org/10.1093/jnci/94.16.1211 ER - TY - JOUR LB - 74. AU - Grote, T AU - Yielding, AL AU - Castillo, R AU - Butler, D AU - Fishkin, E AU - Henry, DH TI - Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial J2 - J Clin Oncol PY - 2005 VL - 23 SP - 9377 EP - 9386 UR - http://dx.doi.org/10.1200/JCO.2005.01.8507 ER - TY - JOUR LB - 75. AU - Ray-Coquard, I AU - Dussart, S AU - Goillot, C AU - Mayeur, D AU - Debourdeau, P AU - Ghesquieres, H TI - A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group J2 - Ann Oncol PY - 2009 VL - 20 SP - 1105 EP - 1112 UR - http://dx.doi.org/10.1093/annonc/mdn750 ER - TY - JOUR LB - 76. AU - Strauss, HG AU - Haensgen, G AU - Dunst, J AU - Hayward, CR AU - Burger, HU AU - Scherhag, A TI - Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer J2 - Int J Gynecol Cancer PY - 2008 VL - 18 SP - 515 EP - 524 UR - http://dx.doi.org/10.1111/j.1525-1438.2007.01032.x ER - TY - JOUR LB - 77. AU - Tjulandin, SA AU - Bias, P AU - Elsasser, R AU - Gertz, B AU - Kohler, E AU - Buchner, A TI - Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial J2 - Arch Drug Inf PY - 2011 VL - 4 SP - 33 EP - 41 UR - http://dx.doi.org/10.1111/j.1753-5174.2011.00035.x ER - TY - JOUR LB - 78. AU - Untch, M AU - Fasching, PA AU - Konecny, GE AU - von Koch, F AU - Conrad, U AU - Fett, W TI - PREPARE trial: a randomized Phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/– darbepoetin alfa in primary breast cancer – results at the time of surgery J2 - Ann Oncol PY - 2011 VL - 22 SP - 1988 EP - 1998 UR - http://dx.doi.org/10.1093/annonc/mdq709 ER - TY - JOUR LB - 79. AU - Österborg, AB AU - Brandberg, Y AU - Hedenus, M TI - Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study J2 - Br J Haematol PY - 2005 VL - 129 SP - 206 EP - 209 UR - http://dx.doi.org/10.1111/j.1365-2141.2005.05440.x ER - TY - JOUR LB - 80. AU - Untch, M AU - Minckwitz, G AU - Konecny, GE AU - Conrad, U AU - Fett, W AU - Kurzeder, C TI - PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis J2 - Ann Oncol PY - 2011 VL - 22 SP - 1999 EP - 2006 UR - http://dx.doi.org/10.1093/annonc/mdq713 ER - TY - JOUR LB - 81. AU - Bajetta, E AU - Vercammen, E AU - Reinhardt, U AU - Janmohamed, R AU - da Costa, RM AU - Matulonis, U TI - Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy J2 - Tumori PY - 2004 VL - 90 SP - 449 EP - 457 ER - TY - JOUR LB - 82. AU - Aapro, M AU - Bajetta, E AU - Freund, M AU - Littlewood, TJ AU - Nortier, JWR AU - Rapoport, B TI - Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy? J2 - Eur J Cancer Suppl PY - 2004 VL - 2 SP - 20 EP - 28 UR - http://dx.doi.org/10.1016/S1359-6349(03)00104-6 ER - TY - JOUR LB - 83. AU - Littlewood, TJ AU - Kallich, JD AU - San Miguel, J AU - Hendricks, L AU - Hedenus, M TI - Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies J2 - J Pain Symptom Manage PY - 2006 VL - 31 SP - 317 EP - 325 UR - http://dx.doi.org/10.1016/j.jpainsymman.2005.08.013 ER - TY - JOUR LB - 84. AU - Vansteenkiste, J AU - Tomita, D AU - Rossi, G AU - Pirker, R TI - Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline J2 - Support Care Cancer PY - 2004 VL - 12 SP - 253 EP - 262 UR - http://dx.doi.org/10.1007/s00520-003-0583-0 ER - TY - JOUR LB - 85. AU - Henry, DH AU - Abels, RI TI - Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies J2 - Semin Oncol PY - 1994 VL - 21 SP - 21 EP - 28 ER - TY - JOUR LB - 86. AU - Case, DC, Jr AU - Bukowski, RM AU - Carey, RW AU - Fishkin, EH AU - Henry, DH AU - Jacobson, RJ TI - Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy J2 - J Natl Cancer Inst PY - 1993 VL - 85 SP - 801 EP - 806 UR - http://dx.doi.org/10.1093/jnci/85.10.801 ER - TY - CONF LB - 87. AU - Coiffier, B AU - Boogaerts, M AU - Kaine, C TI - Impact of Epoetin Beta Versus Standard Care on Quality of Life in Patients with Malignant Disease T2 - 6th Congress of the European Haematology Association DA - June 2001 CY - Frankfurt, Germany ER - TY - BOOK LB - 88. AU - Tonelli, M AU - Lloyd, A AU - Weibe, N AU - Hemmelgarn, B AU - Reiman, T AU - Manns, B TI - Erythropoiesis-Stimulating Agents for Anemia of Cancer or of Chemotherapy: Systematic Review and Economic Evaluation CY - Ottawa PB - Canadian Agency for Drugs and Technologies in Health PY - 2009 ER - TY - BOOK LB - 89. AU - Grant, MD AU - Piper, M AU - Bohlius, J AU - Tonia, T AU - Nadege, R AU - Vikrant, V TI - Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update CY - Chicago, IL PB - Blue Cross and Blue Shield Association Technology Evaluation Center PY - 2013 ER - TY - JOUR LB - 90. AU - Lawrence, DP AU - Kupelnick, B AU - Miller, K AU - Devine, D AU - Lau, J TI - Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients J2 - J Natl Cancer Inst Monogr PY - 2004 SP - 40 EP - 50 UR - http://dx.doi.org/10.1093/jncimonographs/lgh027 ER - TY - JOUR LB - 91. AU - Ross, SD AU - Allen, IE AU - Probst, CA AU - Sercus, B AU - Crean, SM AU - Ranganathan, G TI - Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis J2 - Oncologist PY - 2007 VL - 12 SP - 1264 EP - 1273 UR - http://dx.doi.org/10.1634/theoncologist.12-10-1264 ER - TY - JOUR LB - 92. AU - Shehata, N AU - Walker, I AU - Meyer, R AU - Haynes, AE AU - Imrie, K AU - Cancer Care Ontario Hematology Disease Site Group TI - The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review J2 - Ann Hematol PY - 2008 VL - 87 SP - 961 EP - 973 UR - http://dx.doi.org/10.1007/s00277-008-0525-5 ER - TY - JOUR LB - 93. AU - Kvam, AK AU - Fayers, P AU - Hjermstad, M AU - Gulbrandsen, N AU - Wisloff, F TI - Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations J2 - Eur J Haematol PY - 2009 VL - 83 SP - 279 EP - 289 UR - http://dx.doi.org/10.1111/j.1600-0609.2009.01303.x ER - TY - JOUR LB - 94. AU - Minton, O AU - Stone, P AU - Richardson, A AU - Sharpe, M AU - Hotopf, M TI - Drug therapy for the management of cancer-related fatigue J2 - Cochrane Database Syst Rev PY - 2010 VL - 1 SP - CD006704 UR - http://dx.doi.org/10.1002/14651858.cd006704.pub3 ER - TY - JOUR LB - 95. AU - Bohlius, JS AU - Schmidlin, K AU - Brillant, C AU - Schwarzer, G AU - Trelle, S AU - Seidenfeld, J TI - Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials J2 - Lancet PY - 2009 VL - 373 SP - 1532 EP - 1542 UR - http://dx.doi.org/10.1016/S0140-6736(09)60502-X ER - TY - GEN LB - 96. AU - Amgen Inc TI - Erythropoiesis-Stimulating Agents (Epoetin and Darbepoetin) for Treating Cancer-Treatment Induced Anaemia (Including Review of TA 142): Aranesp® (Darbepoetin Alfa) PY - 2013 CY - Cambridge PB - Amgen Inc ER - TY - GEN LB - 97. AU - Sandoz Ltd TI - Erythropoiesis Agents for Treatment of Cancer-Treatment Induced Anaemia (Incl Review of TA 142): Binocrit® (Epoetin Alfa) PY - 2013 CY - Camberley PB - Scandoz Ltd ER - TY - JOUR LB - 98. AU - Sorgel, F AU - Thyroff-Friesinger, U AU - Vetter, A AU - Vens-Cappell, B AU - Kinzig, M TI - Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial J2 - BMC Clin Pharmacol PY - 2009 VL - 9 SP - 10 UR - http://dx.doi.org/10.1186/1472-6904-9-10 ER - TY - JOUR LB - 99. AU - Sorgel, F AU - Thyroff-Friesinger, U AU - Vetter, A AU - Vens-Cappell, B AU - Kinzig, M TI - Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations J2 - Pharmacology PY - 2009 VL - 83 SP - 122 EP - 130 UR - http://dx.doi.org/10.1159/000189027 ER - TY - JOUR LB - 100. AU - Sorgel, F AU - Thyroff-Friesinger, U AU - Vetter, A AU - Vens-Cappell, B AU - Kinzig, M TI - Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration J2 - Int J Clin Pharmacol Ther PY - 2009 VL - 47 SP - 391 EP - 401 UR - http://dx.doi.org/10.5414/CPP47391 ER - TY - JOUR LB - 101. AU - Weigang-Köhler, K AU - Vetter, A AU - Thyroff-Friesinger, U TI - HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours J2 - Onkologie PY - 2009 VL - 32 SP - 168 EP - 174 UR - http://dx.doi.org/10.1159/000200783 ER - TY - JOUR LB - 102. AU - Haag-Weber, M AU - Vetter, A AU - Thyroff-Friesinger, U AU - INJ-Study Group TI - Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis J2 - Clin Nephrol PY - 2009 VL - 72 SP - 380 EP - 390 ER - TY - CONF LB - 103. AU - Desrame, J AU - Stamerra, O AU - Labourey, JL AU - Toledano, A AU - Dauriac, C AU - Ianotto, JC TI - Haemoglobin Outcomes with Biosimilar Epoetin Alfa in the Management of Chemotherapy-Induced Anaemia in Cancer Patients: First Results From OnCoBOS, A French Observational Study T2 - European Cancer Congress DA - 2013 CY - Amsterdam, the Netherlands ER - TY - CONF LB - 104. AU - Rodriguez Garzotto, A AU - Cortijo Cascajares, S AU - Pernaut Sanchez, C AU - Otero Blas, I AU - Ruiz Ares, G AU - Rebollo Laserna, FJ TI - Use of Erythropoiesis-Stimulating Agents and Comparison of Different Products for the Treatment of Chemotherapy-Induced Anaemia (CIA) T2 - European Cancer Congress DA - 2013 CY - Amsterdam, the Netherlands ER - TY - CONF LB - 105. AU - Lorenz, A AU - Heine, O TI - First Comparison of Biosimilar Epoetin Alfa and Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anaemia T2 - European Cancer Congress DA - 2013 CY - Amsterdam, the Netherlands ER - TY - JOUR LB - 106. AU - Kerkhofs, L AU - Boschetti, G AU - Lugini, A AU - Stanculeanu, DL AU - Palomo, AG TI - Use of biosimilar epoetin to increase haemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience J2 - Future Oncol PY - 2012 VL - 8 SP - 751 EP - 756 UR - http://dx.doi.org/10.2217/fon.12.39 ER - TY - JOUR LB - 107. AU - Delarue, R AU - Haioun, C AU - Coiffier, B AU - Fornecker, L AU - Fournier, M AU - Mounier, N TI - Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study J2 - J Clin Oncol PY - 2011 VL - 29 IS - 15 Suppl. 1 SP - 9048 ER - TY - JOUR LB - 108. AU - Hartmann, JT AU - Metzner, B AU - Binder, C AU - Mergenthaler, HG AU - Rick, O AU - Sayer, HG TI - Addition of darbepoetin alfa to sequential high-dose VIP chemotherapy for patients with advanced metastatic germ cell cancer J2 - J Clin Oncol PY - 2012 VL - 30 IS - Suppl. 1 SP - e15026 ER - TY - CONF LB - 109. AU - Katsumata, N AU - Fujiwara, Y AU - Katakami, N AU - Nishiwaki, Y AU - Tsuboi, M AU - Takeda, K TI - Randomized, Double Blind, Placebo-Controlled Phase III Study of Weekly Administration of Darbepoetin Alfa in Anemic Patients with Lung or Gynecologic Cancer Receiving Platinum-Containing Chemotherapy T2 - 20th Regional Congress of the International Society of Blood Transfusion DA - November 2009 CY - Nagoya, Japan ER - TY - JOUR LB - 110. AU - Nitz, U AU - Oberhoff, C AU - Reimer, T AU - Schumacher, C AU - Hackmann, J AU - Warm, M TI - Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the Phase III ARA plus trial J2 - Cancer Res PY - 2009 VL - 69 IS - Suppl. SP - 4100 UR - http://dx.doi.org/10.1158/0008-5472.SABCS-4100 ER - TY - JOUR LB - 111. AU - Suzuki, Y AU - Tokuda, Y AU - Okamoto, R AU - Nakagawa, K AU - Ando, K AU - Iwata, H TI - Randomized, placebo-controlled Phase II study of darbepoetin alfa (DA) administered every three weeks (Q3W) in patients with chemotherapyinduced anemia (CIA). 34th Congress of the European Society for Medical Oncology (ESMO), Stockholm, Sweden, September 2008 J2 - Ann Oncol PY - 2008 VL - 19 SP - viii277 ER - TY - JOUR LB - 112. AU - Cella, D AU - Eton, DT AU - Lai, JS AU - Peterman, AH AU - Merkel, DE TI - Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales J2 - J Pain Symptom Manage PY - 2002 VL - 24 SP - 547 EP - 561 UR - http://dx.doi.org/10.1016/S0885-3924(02)00529-8 ER - TY - BOOK LB - 113. AU - Drummond, MF AU - Sculpher, MJ AU - Forrance, GN AU - O‘Brien, BS AU - Stoddart, GL TI - Methods for the Economic Evaluation of Health Care Programmes CY - 3rd edn. Oxford PB - Oxford University Press PY - 2005 ER - TY - JOUR LB - 114. AU - Barosi, G AU - Marchetti, M AU - Liberato, NL TI - Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia J2 - Br J Cancer PY - 1998 VL - 78 SP - 781 EP - 787 UR - http://dx.doi.org/10.1038/bjc.1998.579 ER - TY - JOUR LB - 115. AU - Cremieux, PY AU - Finkelstein, SN AU - Berndt, ER AU - Crawford, J AU - Slavin, MB TI - Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anaemia J2 - Pharmacoeconomics PY - 1999 VL - 16 SP - 459 EP - 472 UR - http://dx.doi.org/10.2165/00019053-199916050-00004 ER - TY - JOUR LB - 116. AU - Martin, SC AU - Gagnon, DD AU - Zhang, L AU - Bokemeyer, C AU - Van Marwijk Kooy, M AU - van Hout, B TI - Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer J2 - Pharmacoeconomics PY - 2003 VL - 21 SP - 1153 EP - 1169 UR - http://dx.doi.org/10.2165/00019053-200321160-00002 ER - TY - JOUR LB - 117. AU - Ortega, A AU - Dranitsaris, G AU - Puodziunas, AL TI - What are cancer patients willing to pay for prophylactic epoetin alfa? A cost–benefit analysis PY - 1998 VL - 83 SP - 2588 EP - 2596 ER - TY - JOUR LB - 118. AU - Sheffield, RE AU - Sullivan, SD AU - Saltiel, E AU - Nishimura, L TI - Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia J2 - Ann Pharmacother PY - 1997 VL - 31 SP - 15 EP - 22 ER - TY - JOUR LB - 119. AU - Evers, S AU - Goossens, M AU - de Vet, H AU - van Tulder, M AU - Ament, A TI - Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria J2 - Int J Technol Assess Health Care PY - 2005 VL - 21 SP - 240 EP - 245 ER - TY - JOUR LB - 120. AU - Philips, Z AU - Ginnely, L AU - Sculpher, M AU - Claxton, K AU - Golder, S AU - Riemsma, R TI - Review of guidelines for good practice in decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment J2 - Health Technol Assess PY - 2004 VL - 8 IS - 36 UR - http://dx.doi.org/10.3310/hta8360 ER - TY - JOUR LB - 121. AU - Fagnoni, P AU - Limat, S AU - Chaigneau, L AU - Briaud, S AU - Schmitt, B AU - Merrouche, Y TI - Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer J2 - Support Care Cancer PY - 2006 VL - 14 SP - 1030 EP - 1037 UR - http://dx.doi.org/10.1007/s00520-006-0062-5 ER - TY - JOUR LB - 122. AU - Glaspy, J AU - Tchekmedyian, N AU - Gupta, S TI - PCN17: comparing the cost-effectiveness of 3 mcg/kg Q2W darbepoetin alfa with standard dose epoetin alfa for anemia management in chemotherapy-treated cancer patients in United States J2 - Value Health PY - 2002 VL - 5 SP - 543 UR - http://dx.doi.org/10.1016/S1098-3015(10)61433-7 ER - TY - JOUR LB - 123. AU - Borget, I AU - Tilleul, P AU - Joly, AC AU - Chouaid, C TI - Incremental cost-effectiveness ratio of darbepoetin alfa (Aranesp (R)) in the treatment of chemotherapy-induced anemia in lung cancer patients J2 - Value Health PY - 2006 VL - 9 SP - A278 EP - A279 UR - http://dx.doi.org/10.1016/S1098-3015(10)63440-7 ER - TY - JOUR LB - 124. AU - Ben-Hamadi, R AU - Duh, MS AU - Aggarwal, J AU - Henckler, A AU - McKenzie, RS AU - Tak Piech, C TI - The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia J2 - Curr Med Res Opin PY - 2005 VL - 21 SP - 1677 EP - 1682 UR - http://dx.doi.org/10.1185/030079905X65501 ER - TY - JOUR LB - 125. AU - Persson, U AU - Borg, S AU - Jansson, S AU - Ekman, T AU - Franksson, L AU - Friesland, S TI - Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response J2 - Adv Ther PY - 2005 VL - 22 SP - 208 EP - 224 UR - http://dx.doi.org/10.1007/BF02849930 ER - TY - JOUR LB - 126. AU - Spaepen, E AU - Demarteau, N AU - Van Belle, S AU - Annemans, L TI - Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals J2 - Oncologist PY - 2008 VL - 13 SP - 596 EP - 607 UR - http://dx.doi.org/10.1634/theoncologist.2007-0219 ER - TY - JOUR LB - 127. AU - Pashos, CL AU - Larholt, K AU - Fraser, KA AU - McKenzie, RS AU - Senbetta, M AU - Piech, CT TI - Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia J2 - Support Care Cancer PY - 2012 VL - 20 SP - 159 EP - 165 UR - http://dx.doi.org/10.1007/s00520-010-1083-7 ER - TY - JOUR LB - 128. AU - Cornes, P AU - Coiffier, B AU - Zambrowski, JJ TI - Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option J2 - Curr Med Res Opin PY - 2007 VL - 23 SP - 357 EP - 368 UR - http://dx.doi.org/10.1185/030079906X167282 ER - TY - JOUR LB - 129. AU - Herrmann, R TI - Erythropoietin therapy in cancer-related anaemia, yes or no? J2 - Intern Med J PY - 2008 VL - 38 SP - 749 EP - 750 UR - http://dx.doi.org/10.1111/j.1445-5994.2008.01767.x ER - TY - JOUR LB - 130. AU - Marchetti, M AU - Barosi, G TI - Clinical and economic impact of epoetins in cancer care J2 - Pharmacoeconomics PY - 2004 VL - 22 SP - 1029 EP - 1045 UR - http://dx.doi.org/10.2165/00019053-200422160-00001 ER - TY - JOUR LB - 131. AU - Reeder, CE TI - Anemia in cancer and critical care patients: pharmacoeconomic considerations J2 - Am J Health Syst Pharm PY - 2007 VL - 64 SP - S22 EP - S27 UR - http://dx.doi.org/10.2146/ajhp060603 ER - TY - JOUR LB - 132. AU - Stasi, R AU - Amadori, S AU - Littlewood, TJ AU - Terzoli, E AU - Newland, AC AU - Provan, D TI - Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns J2 - Oncologist PY - 2005 VL - 10 SP - 539 EP - 554 UR - http://dx.doi.org/10.1634/theoncologist.10-7-539 ER - TY - JOUR LB - 133. AU - Repetto, L AU - Moeremans, K AU - Annemans, L TI - European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment J2 - Cancer Treat Rev PY - 2006 VL - 32 SP - S5 EP - S9 UR - http://dx.doi.org/10.1016/j.ctrv.2006.04.007 ER - TY - JOUR LB - 134. AU - Roungrong, J TI - Cost utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand J2 - J Med Assoc Thai PY - 2008 VL - 91 IS - Suppl. 2 SP - S119 EP - S125 ER - TY - JOUR LB - 135. AU - Roungrong, J AU - Teerawattananon, Y AU - Chaikledkaew, U TI - Cost–utility analysis of recombinant human erythropoietin in anaemic cancer patients induced by chemotherapy in Thailand J2 - J Med Assoc Thailand PY - 2008 VL - 91 IS - Suppl. 2 SP - S119 EP - S125 ER - TY - JOUR LB - 136. AU - Griggs, JJ TI - Cost–utility of erythropoietin in the treatment of cancer-related anemia J2 - Med Decis Making PY - 1997 VL - 17 SP - 529 ER - TY - JOUR LB - 137. AU - Griggs, JJ TI - Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia J2 - Anticancer Drugs PY - 1998 VL - 9 SP - 925 EP - 932 UR - http://dx.doi.org/10.1097/00001813-199811000-00012 ER - TY - CONF LB - 138. AU - Malonne, H TI - Cost evaluation of erythropoiesis stimulating agents in the treatment of platinum chemotherapy induced anaemia T2 - 20th Annual Meeting of the Belgian Hematology Society DA - January 2005 CY - Genval, Belgium ER - TY - JOUR LB - 139. AU - Borget, I AU - Tilleul, P AU - Baud, M AU - Joly, AC AU - Chouaid, C TI - Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis J2 - Pharm World Sci PY - 2007 VL - 29 SP - 454 ER - TY - JOUR LB - 140. AU - Chouaid, C AU - Borget, I AU - Baud, M AU - Joly, AC AU - Daguenel, A AU - Tilleul, P TI - Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis J2 - Lung Cancer PY - 2005 VL - 49 SP - S23 UR - http://dx.doi.org/10.1016/S0169-5002(05)80192-8 ER - TY - JOUR LB - 141. AU - Finek, J AU - Holubec, L AU - Wiesnerova, A AU - Pav, Z AU - Dusek, V TI - Darbepoetin alfa versus epoetin alfa for treatment of chemotherapy-induced anemia: a health economic evaluation J2 - Ann Oncol PY - 2010 VL - 21 IS - Suppl. 8 SP - 344 ER - TY - JOUR LB - 142. AU - Klarenbach, S AU - Manns, B AU - Reiman, T AU - Reaume, MN AU - Lee, H AU - Lloyd, A TI - Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer J2 - Cancer PY - 2010 VL - 116 SP - 3224 EP - 3232 UR - http://dx.doi.org/10.1002/cncr.25052 ER - TY - CONF LB - 143. AU - Szucs, TD AU - Boogaerts, M AU - Coiffier, B AU - Kainz, C TI - Cost-effectiveness of epoetin beta in the management of cancer-related anaemia T2 - 6th Annual Congress of the European Haematology Association DA - 21–24 June 2001 CY - Frankfurt, Germany ER - TY - JOUR LB - 144. AU - Cremieux, P AU - Greenberg, P AU - Piech, CT TI - Epoetin alfa is more effective and less costly relative to darbepoetin alfa in lung cancer patients receiving treatment for chemotherapy-induced anemia J2 - Proc Am Soc Clin Oncol PY - 2003 VL - 22 SP - 559 ER - TY - JOUR LB - 145. AU - Fragoulakis, V AU - Maniadakis, N TI - Economic evaluation of darbepoetin alpha in the management of patients with chemotherapy induced anemia (CIA) in Greece J2 - Value Health PY - 2011 VL - 14 SP - A440 UR - http://dx.doi.org/10.1016/j.jval.2011.08.1139 ER - TY - JOUR LB - 146. AU - Mark, TL AU - McKenzie, SR AU - Piech, CT TI - Better early and overall hematologic outcomes and lower drug cost with epoetin alfa (EPO) compared with darbepoetin alfa (DARB) J2 - Blood PY - 2003 VL - 102 SP - 510B ER - TY - JOUR LB - 147. AU - van Hout, BA AU - Gagnon, DD TI - The cost-effectiveness of epoetin alfa (Eprex) and darbepoetin alfa (Aranesp) in the treatment of chemotherapy-related anemia J2 - Hematol J PY - 2004 VL - 5 SP - S176 EP - S177 ER - TY - JOUR LB - 148. AU - Ben-Hamadi, R AU - Duh, MS AU - Henckler, A AU - McKenzie, S AU - Fastenau, J AU - Piech, CT TI - Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy-induced anemia J2 - J Clin Oncol PY - 2005 VL - 23 SP - 551S UR - http://dx.doi.org/10.1016/s1098-3015(10)62574-0 ER - TY - JOUR LB - 149. AU - Van Bellinghen, LA AU - Demarteau, N AU - Annemans, L AU - Bracco, A TI - A cost–consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (QW_EB) in patients with chemotherapy-induced anemia (CIA): a retrospective study J2 - Value Health PY - 2006 VL - 9 SP - A286 UR - http://dx.doi.org/10.1016/S1098-3015(10)63463-8 ER - TY - JOUR LB - 150. AU - Esposito, G AU - Lamotte, M AU - Annemans, L AU - Bracco, A TI - Cost–consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (QW_EB) in patients with chemotherapy-induced anemia (CIA): the Italian case J2 - Value Health PY - 2007 VL - 10 SP - A324 UR - http://dx.doi.org/10.1016/S1098-3015(10)65166-2 ER - TY - JOUR LB - 151. AU - Van Bellinghen, LA AU - Esposito, G AU - Lamotte, M AU - Bracco, A AU - Goertz, A AU - Annemans, L TI - A cost–consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (QW_EB) in patients with chemotherapy-induced anemia (CIA): the German case J2 - Value Health PY - 2007 VL - 10 SP - A328 UR - http://dx.doi.org/10.1016/S1098-3015(10)65177-7 ER - TY - JOUR LB - 152. AU - Finek, J AU - Holubec, L AU - Wiesnerova, A AU - Pav, Z AU - Dusek, L TI - Darbepoetin alfa versus epoetin alfa for treatment of chemotherapy-induced anemia: a health economic evaluation J2 - Value Health PY - 2010 VL - 13 SP - A465 UR - http://dx.doi.org/10.1016/S1098-3015(11)72978-3 ER - TY - JOUR LB - 153. AU - Liwing, J AU - Nasman, P AU - Kernell, H AU - Gagnon, DD AU - Wu, Y TI - Cost-effectiveness modelling of epoetin alfa and darbepoetin alfa in the treatment of chemotherapy-related anaemia in Sweden J2 - Value Health PY - 2010 VL - 13 SP - A38 UR - http://dx.doi.org/10.1016/S1098-3015(10)72167-7 ER - TY - JOUR LB - 154. AU - Walter, E AU - Ribnicsek, E AU - Kutikova, L TI - Economic evaluation of darbepoetin alfa (Aranesp) compared to epoetin alfa (Erypo) and epoetin beta (NeoRecormon) in the treatment of chemotherapy-induced anemia (CIA) in Austria J2 - Value Health PY - 2010 VL - 13 SP - A377 UR - http://dx.doi.org/10.1016/S1098-3015(11)72530-X ER - TY - JOUR LB - 155. AU - Duh, MS AU - Weiner, JR AU - White, LA AU - Lefebvre, P AU - Greenberg, PE TI - Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents J2 - Pharmacoeconomics PY - 2008 VL - 26 SP - 99 EP - 120 UR - http://dx.doi.org/10.2165/00019053-200826020-00002 ER - TY - JOUR LB - 156. AU - Borg, S AU - Glenngard, AH AU - Österborg, A AU - Persson, U TI - The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model J2 - Acta Oncol PY - 2008 VL - 47 SP - 1009 EP - 1017 UR - http://dx.doi.org/10.1080/02841860701744498 ER - TY - JOUR LB - 157. AU - Borget, I AU - Tilleul, P AU - Baud, M AU - Joly, AC AU - Daguenel, A AU - Chouaid, C TI - Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis J2 - Lung Cancer PY - 2006 VL - 51 SP - 369 EP - 376 UR - http://dx.doi.org/10.1016/j.lungcan.2005.10.024 ER - TY - JOUR LB - 158. AU - Aapro, M AU - Cornes, P AU - Sun, D AU - Abraham, I TI - Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer J2 - Ther Adv Med Oncol PY - 2012 VL - 4 SP - 95 EP - 105 UR - http://dx.doi.org/10.1177/1758834012444499 ER - TY - JOUR LB - 159. AU - Ossa, DF AU - Briggs, A AU - McIntosh, E AU - Cowell, W AU - Littlewood, T AU - Sculpher, M TI - Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods J2 - Pharmacoeconomics PY - 2007 VL - 25 SP - 223 EP - 237 UR - http://dx.doi.org/10.2165/00019053-200725030-00005 ER - TY - JOUR LB - 160. AU - Reed, SD AU - Radeva, JI AU - Daniel, DB AU - Mody, SH AU - Forlenza, JB AU - McKenzie, RS TI - Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial J2 - Pharmacoeconomics PY - 2006 VL - 24 SP - 479 EP - 494 UR - http://dx.doi.org/10.2165/00019053-200624050-00006 ER - TY - JOUR LB - 161. AU - Casadevall, N AU - Durieux, P AU - Dubois, S AU - Hemery, F AU - Lepage, E AU - Quarre, MC TI - Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial J2 - Blood PY - 2004 VL - 104 SP - 321 EP - 327 UR - http://dx.doi.org/10.1182/blood-2003-07-2252 ER - TY - JOUR LB - 162. AU - Crawford, J AU - Cella, D AU - Cleeland, CS AU - Cremieux, PY AU - Demetri, GD AU - Sarokhan, BJ TI - Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy J2 - Cancer PY - 2002 VL - 95 SP - 888 EP - 895 UR - http://dx.doi.org/10.1002/cncr.10763 ER - TY - CONF LB - 163. AU - Evers, S TI - CHEC Project T2 - The Netherlands: Maastricht University PY - 2015 UR - www.maastrichtuniversity.nl/web/Institutes/Theme/DepartmentsCAPHRI/HealthServicesResearch/ResearchHSR/CHECProject.htm Y2 - 12 November 2015 ER - TY - JOUR LB - 164. AU - Glaspy, J AU - Bukowski, R AU - Steinberg, D AU - Taylor, C AU - Tchekmedyian, S AU - Vadhan-Raj, S TI - Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community Oncology practice. Procrit Study Group J2 - J Clin Oncol PY - 1997 VL - 15 SP - 1218 EP - 1234 ER - TY - JOUR LB - 165. AU - Abels, RI TI - Recombinant human erythropoietin in the treatment of the anaemia of cancer J2 - Acta Haematol PY - 1992 VL - 87 IS - Suppl. 1 SP - 4 EP - 11 UR - http://dx.doi.org/10.1159/000204780 ER - TY - BOOK LB - 166. AU - Joint Formulary Committee TI - British National Formulary ET - 66 ed. CY - London PB - BMJ Group and Pharmaceutical Press PY - 2013 ER - TY - JOUR LB - 167. AU - Witzig, TE AU - Silberstein, PT AU - Loprinzi, CL AU - Sloan, JA AU - Novotny, PJ AU - Mailliard, JA TI - Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy J2 - J Clin Oncol PY - 2005 VL - 23 SP - 2606 EP - 2617 UR - http://dx.doi.org/10.1200/JCO.2004.10.020 ER - TY - JOUR LB - 168. AU - Kotasek, D AU - Canon, J-L AU - San Miguel, J AU - Hedenus, M AU - Hendricks, L AU - Rossi, G TI - Correction/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized Phase 3 active controlled trial J2 - Blood PY - 2004 VL - 104 SP - 1636 ER - TY - BOOK LB - 169. AU - National Institute for Health and Care Excellence TI - Guide to the Methods of Technology Appraisal CY - London PB - NICE PY - 2013 ER - TY - ELEC LB - 170. AU - Latimer, N TI - NICE DSU Technical Support Document 14: Undertaking Survival Analysis for Economic Evaluations Alongside Clinical Trials – Extrapolation with Patient-Level Data UR - www.nicedsu.org.uk/ M1 - 16 August 2015 ER - TY - JOUR LB - 171. AU - Latimer, NR TI - Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data: inconsistencies, limitations, and a practical guide J2 - Med Decis Making PY - 2013 VL - 33 SP - 743 EP - 754 ER - TY - JOUR LB - 172. AU - Varney, SJ AU - Guest, JF TI - The annual cost of blood transfusions in the UK. Transfusion medicine (Oxford, England) PY - 2003 VL - 13 SP - 205 EP - 218 UR - http://dx.doi.org/10.1046/j.1365-3148.2003.00443.x ER - TY - BOOK LB - 173. AU - Office for National Statistics TI - Interim Life Tables, 2010–2012 CY - London PB - ONS PY - 2013 UR - www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2010-2012/index.html Y2 - 8 August 2015 ER - TY - JOUR LB - 174. AU - Ossa, DF AU - Briggs, A AU - Cowell, W AU - Littlewood, T AU - Sculpher, M TI - Utility associated with severity of cancer-related anaemia (CRA): a societal valuation J2 - Value Health PY - 2004 VL - 7 SP - 680 UR - http://dx.doi.org/10.1016/s1098-3015(10)65767-1 ER - TY - JOUR LB - 175. AU - Papaioannou, D AU - Brazier, J AU - Paisley, S J2 - NICE DSU Technical Support Document 9: the Identification, Review and Synthesis of Health State Utility Values from the Literature PY - 2010 UR - www.nicedsu.org.uk/ Y2 - 16 August 2015 ER - TY - JOUR LB - 176. AU - Harrow, BS AU - Eaton, CB AU - Roberts, MB AU - Assaf, AR AU - Luo, X AU - Chen, Z TI - Health utilities associated with hemoglobin levels and blood loss in postmenopausal women: the Women’s Health Initiative J2 - Value Health PY - 2011 VL - 14 SP - 555 EP - 563 UR - http://dx.doi.org/10.1016/j.jval.2010.11.008 ER - TY - JOUR LB - 177. AU - Lloyd, A AU - van Hanswijck de Jonge, P AU - Doyle, S AU - Cornes, P TI - Health state utility scores for cancer-related anemia through societal and patient valuations J2 - Value Health PY - 2008 VL - 11 SP - 1178 EP - 1185 UR - http://dx.doi.org/10.1111/j.1524-4733.2008.00394.x ER - TY - JOUR LB - 178. AU - Tajima, R AU - Kondo, M AU - Kai, H AU - Saito, C AU - Okada, M AU - Takahashi, H TI - Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D) J2 - Clin Exp Nephrol PY - 2010 VL - 14 SP - 340 EP - 348 UR - http://dx.doi.org/10.1007/s10157-010-0304-1 ER - TY - JOUR LB - 179. AU - Wisloff, F AU - Gulbrandsen, N AU - Hjorth, M AU - Lenhoff, S AU - Fayers, P TI - Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes J2 - Eur J Haematol PY - 2005 VL - 75 SP - 293 EP - 298 UR - http://dx.doi.org/10.1111/j.1600-0609.2005.00509.x ER - TY - JOUR LB - 180. AU - Dakin, H TI - Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database J2 - Health Qual Life Outcomes PY - 2013 VL - 11 SP - 151 UR - http://dx.doi.org/10.1186/1477-7525-11-151 ER - TY - JOUR LB - 181. AU - Brazier, J AU - Roberts, J AU - Tsuchiya, A AU - Busschbach, J TI - A comparison of the EQ-5D and SF-6D across seven patient groups J2 - Health Econ PY - 2004 VL - 13 SP - 873 EP - 884 UR - http://dx.doi.org/10.1002/hec.866 ER - TY - JOUR LB - 182. AU - Ara, R AU - Brazier, JE TI - Populating an economic model with health state utility values: moving toward better practice J2 - Value Health PY - 2010 VL - 13 SP - 509 EP - 518 UR - http://dx.doi.org/10.1111/j.1524-4733.2010.00700.x ER - TY - BOOK LB - 183. AU - Office for National Statistics TI - Statistical Bulletin: Cancer Registration Statistics, England, 2011 CY - London PB - ONS PY - 2011 UR - www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/no--42--2011/stb-cancer-statistics-registrations-2011.html Y2 - 8 August 2015 ER - TY - JOUR LB - 184. AU - Tengs, TO AU - Wallace, A TI - One thousand health-related quality-of-life estimates J2 - Med Care PY - 2000 VL - 38 SP - 583 EP - 637 UR - http://dx.doi.org/10.1097/00005650-200006000-00004 ER - TY - JOUR LB - 185. AU - Hoyle, M AU - Crathorne, L AU - Peters, J AU - Jones-Hughes, T AU - Cooper, C AU - Napier, M TI - The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal no.150 and part review of technology appraisal no. 118): a systematic review and economic model J2 - Health Technol Assess PY - 2013 VL - 17 IS - 14 UR - http://dx.doi.org/10.3310/hta17140 ER - TY - JOUR LB - 186. AU - Pavey, T AU - Hoyle, M AU - Ciani, O AU - Crathorne, L AU - Jones-Hughes, T AU - Cooper, C TI - Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses J2 - Health Technol Assess PY - 2012 VL - 16 IS - 42 UR - http://dx.doi.org/10.3310/hta16420 ER - TY - BOOK LB - 187. AU - Curtis, L TI - Unit Costs of Health and Social Care 2012 CY - Canterbury PB - Personal Social Services Research Unit PY - 2012 ER - TY - BOOK LB - 188. AU - Curtis, L TI - Unit Costs of Health and Social Care 2013 CY - Canterbury PB - Personal Social Services Research Unit PY - 2013 ER - TY - BOOK LB - 189. AU - Information Centre TI - 2006/07 UK General Practice Workload Survey CY - Leeds PB - The Information Centre PY - 2007 ER - TY - BOOK LB - 190. AU - Department of Health TI - NHS Reference Costs 2012–2013 CY - London PB - Department of Health PY - 2013 ER - TY - BOOK LB - 191. AU - NHS Blood and Transplant TI - NHSBT Price List 2013/2014 CY - London PB - Department of Health PY - 2013 ER - TY - BOOK LB - 192. AU - National Commissioning Group for Blood TI - Update on the Cost of Blood Components and Prices for the Provision of Diagnostic Services for 2008/09 from the National Blood Service (NBS) CY - London PB - Department of Health PY - 2007 ER - TY - JOUR LB - 193. AU - Vaupel, P TI - Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis J2 - Oncologist PY - 2008 VL - 13 SP - 21 EP - 26 UR - http://dx.doi.org/10.1634/theoncologist.13-S3-21 ER - TY - JOUR LB - 194. AU - Arcasoy, MO AU - Amin, K AU - Chou, SC AU - Haroon, ZA AU - Varia, M AU - Raleigh, JA TI - Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia J2 - Clin Cancer Res PY - 2005 VL - 11 SP - 20 EP - 27 ER - TY - BOOK LB - 195. AU - Nunnaly, JC TI - Psychometric Theory ET - 2nd edn. CY - New York, NY PB - McGraw Hill PY - 1978 ER - TY - JOUR LB - 196. AU - Cazzola, M AU - Beguin, Y TI - New tools for clinical evaluation of erythron function in man J2 - Br J Haematol PY - 1992 VL - 80 SP - 278 EP - 284 UR - http://dx.doi.org/10.1111/j.1365-2141.1992.tb08133.x ER - TY - JOUR LB - 197. AU - Durie, BG AU - Salmon, SE TI - A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival J2 - Cancer PY - 1975 VL - 36 SP - 842 EP - 854 UR - http://dx.doi.org/10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U ER - TY - JOUR LB - 198. AU - Moebus, V AU - Jackisch, C AU - Lueck, HJ AU - du Bois, A AU - Thomssen, C AU - Kurbacher, C TI - Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study J2 - J Clin Oncol PY - 2010 VL - 28 SP - 2874 EP - 2880 UR - http://dx.doi.org/10.1200/JCO.2009.24.7643 ER - TY - JOUR LB - 199. AU - Moebus, V AU - Untch, M AU - du Bois, A AU - Lueck, HJ AU - Thomssen, C AU - Kuhn, W TI - Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial J2 - J Clin Oncol PY - 2004 VL - 22 IS - Suppl. ER - TY - JOUR LB - 200. AU - Moebus, VJ AU - Lueck, HJ AU - Thomssen, C AU - Kuhn, W AU - Kurbacher, C AU - Nitz, U TI - Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 + LN). Mature results of an AGO-trial J2 - Breast Cancer Res Treat PY - 2007 VL - 103 ER - TY - JOUR LB - 201. AU - Ray-Coquard, I AU - Le Cesne, A AU - Rubio, MT AU - Mermet, J AU - Maugard, C AU - Ravaud, A TI - Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group J2 - J Clin Oncol PY - 1999 VL - 17 SP - 2840 EP - 2846 ER - TY - JOUR LB - 202. AU - Tchekmedyian, NS AU - Kallich, J AU - McDermott, A AU - Fayers, P AU - Erder, MH TI - The relationship between psychologic distress and cancer-related fatigue J2 - Cancer PY - 2003 VL - 98 SP - 198 EP - 203 UR - http://dx.doi.org/10.1002/cncr.11463 ER - TY - JOUR LB - 203. AU - Bokemeyer, C AU - Aapro, MS AU - Courdi, A AU - Foubert, J AU - Link, H AU - Österborg, A TI - EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer J2 - Eur J Cancer PY - 2004 VL - 40 SP - 2201 EP - 2216 UR - http://dx.doi.org/10.1016/j.ejca.2004.07.015 ER - TY - JOUR LB - 204. AU - Minton, O AU - Stone, P AU - Richardson, A AU - Sharpe, M AU - Hotopf, M TI - Drug therapy for the management of cancer related fatigue J2 - Cochrane Database Syst Rev PY - 2008 VL - 1 SP - CD006704 UR - http://dx.doi.org/10.1002/14651858.cd006704.pub2 ER - TY - JOUR LB - 205. AU - Minton, O AU - Richardson, A AU - Sharpe, M AU - Hotopf, M AU - Stone, P TI - A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue J2 - J Natl Cancer Inst PY - 2008 VL - 100 SP - 1155 EP - 1166 UR - http://dx.doi.org/10.1093/jnci/djn250 ER - TY - JOUR LB - 206. AU - Bohlius, J AU - Wilson, J AU - Seidenfeld, J AU - Piper, M AU - Schwarzer, G AU - Sandercock, J TI - Erythropoietin or darbepoetin for patients with cancer J2 - Cochrane Database Syst Rev PY - 2006 VL - 3 SP - CD003407 UR - http://dx.doi.org/10.1002/14651858.cd003407.pub4 ER - TY - JOUR LB - 207. AU - Bohlius, J AU - Langensiepen, S AU - Schwarzer, G AU - Seidenfeld, J AU - Piper, M AU - Bennett, C TI - Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J2 - J Natl Cancer Inst PY - 2005 VL - 97 SP - 489 EP - 498 UR - http://dx.doi.org/10.1093/jnci/dji087 ER - TY - JOUR LB - 208. AU - Bohlius, J AU - Wilson, J AU - Seidenfeld, J AU - Piper, M AU - Schwarzer, G AU - Sandercock, J TI - Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J2 - J Natl Cancer Inst PY - 2006 VL - 98 SP - 708 EP - 714 UR - http://dx.doi.org/10.1093/jnci/djj189 ER - TY - JOUR LB - 209. AU - Bohlius, JF AU - Langensiepen, S AU - Engert, A AU - Schwarzer, G AU - Bennett, CL TI - Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review J2 - Best Pract Res Clin Haematol PY - 2005 VL - 18 SP - 449 EP - 454 UR - http://dx.doi.org/10.1016/j.beha.2005.01.022 ER - TY - JOUR LB - 210. AU - Bamias, A AU - Aravantinos, G AU - Kalofonos, C AU - Timotheadou, N AU - Siafaka, V AU - Vlahou, I TI - Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group J2 - Oncology PY - 2003 VL - 64 SP - 102 EP - 110 UR - http://dx.doi.org/10.1159/000067766 ER - TY - JOUR LB - 211. AU - Cascinu, S AU - Fedeli, A AU - Del Ferro, E AU - Luzi Fedeli, S AU - Catalano, G TI - Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo J2 - J Clin Oncol PY - 1994 VL - 12 SP - 1058 EP - 1062 ER - TY - JOUR LB - 212. AU - Cazzola, M AU - Messinger, D AU - Battistel, V AU - Bron, D AU - Cimino, R AU - Enller-Ziegler, L TI - Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response J2 - Blood PY - 1995 VL - 86 SP - 4446 EP - 4453 ER - TY - JOUR LB - 213. AU - Iconomou, G AU - Koutras, A AU - Rigopoulos, A AU - Vagenakis, AG AU - Kalofonos, HP TI - Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial J2 - J Pain Symptom Manage PY - 2003 VL - 25 SP - 512 EP - 518 UR - http://dx.doi.org/10.1016/S0885-3924(03)00070-8 ER - TY - JOUR LB - 214. AU - Kunikane, H AU - Watanabe, K AU - Fukuoka, M AU - Saijo, N AU - Furuse, K AU - Ikegami, H TI - Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer J2 - Int J Clin Oncol PY - 2001 VL - 6 SP - 296 EP - 301 UR - http://dx.doi.org/10.1007/s10147-001-8031-y ER - TY - JOUR LB - 215. AU - Oberhoff, C AU - Neri, B AU - Amadori, D AU - Petry, KU AU - Gamucci, T AU - Rebmann, U TI - Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study J2 - Ann Oncol PY - 1998 VL - 9 SP - 255 EP - 260 UR - http://dx.doi.org/10.1023/A:1008296622469 ER - TY - JOUR LB - 216. AU - Österborg, A AU - Boogaerts, MA AU - Cimino, R AU - Essers, U AU - Holowiecki, J AU - Juliusson, G TI - Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma – a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma J2 - Blood PY - 1996 VL - 87 SP - 2675 EP - 2682 ER - TY - JOUR LB - 217. AU - Rosen, FR AU - Haraf, DJ AU - Kies, MS AU - Stenson, K AU - Portugal, L AU - List, MA TI - Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer J2 - Clin Cancer Res PY - 2003 VL - 9 SP - 1689 EP - 1697 ER - TY - CONF LB - 218. AU - Throuvalas, N AU - Antonadu, D AU - Boufi, M AU - Lavey, RS AU - Malamos, N TI - Erythropoietin decreases transfusion requirements during radiochemotherapy T2 - American Society of Clinical Oncology Annual Meeting DA - May 2000 CY - New Orleans, LA, USA ER - TY - JOUR LB - 219. AU - Welch, RS AU - James, RD AU - Wilkinson, PM AU - Belli, F AU - Cowan, RA TI - Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer J2 - Canc J Sci Am PY - 1995 VL - 1 SP - 261 EP - 266 ER - TY - JOUR LB - 220. AU - Aapro, M AU - Scherhag, A AU - Burger, HU TI - Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients J2 - Br J Cancer PY - 2008 VL - 99 SP - 14 EP - 22 UR - http://dx.doi.org/10.1038/sj.bjc.6604408 ER - TY - JOUR LB - 221. AU - Aapro, M AU - Scherhag, A AU - Osterwalder, B AU - Ukarma, L AU - Burger, HU TI - Epoetin beta treatment in patients with cancer chemotherapy induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. International MASCC/IS00 Symposium, Rome, June 2009 J2 - Support Care Cancer PY - 2009 VL - 17 SP - 1036 EP - 1037 ER - TY - JOUR LB - 222. AU - Berndt, E AU - Kallich, J AU - McDermott, A AU - Xu, X AU - Lee, H AU - Glaspy, J TI - Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy J2 - Pharmacoeconomics PY - 2005 VL - 23 SP - 505 EP - 514 UR - http://dx.doi.org/10.2165/00019053-200523050-00009 ER - TY - JOUR LB - 223. AU - Blohmer, JU AU - Paepke, S AU - Sehouli, J AU - Boehmer, D AU - Kolben, M AU - Wurschmidt, F TI - Randomized Phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study J2 - J Clin Oncol PY - 2011 VL - 29 SP - 3791 EP - 3797 UR - http://dx.doi.org/10.1200/JCO.2010.30.4899 ER - TY - JOUR LB - 224. AU - Cabanillas, ME AU - Kantarjian, H AU - Thomas, DA AU - Mattiuzzi, GN AU - Rytting, ME AU - Bruera, E TI - Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial J2 - Cancer PY - 2012 VL - 118 SP - 848 EP - 855 UR - http://dx.doi.org/10.1002/cncr.26341 ER - TY - JOUR LB - 225. AU - Chang, J AU - Couture, FA AU - Young, SD AU - Lau, CY AU - McWatters, KL TI - Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy J2 - Support Cancer Ther PY - 2004 VL - 2 SP - 52 EP - 58 UR - http://dx.doi.org/10.3816/SCT.2004.n.023 ER - TY - JOUR LB - 226. AU - Charu, V AU - Belani, CP AU - Gill, AN AU - Bhatt, M AU - Tomita, D AU - Rossi, G TI - Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label Phase II trial J2 - Oncologist PY - 2007 VL - 12 SP - 727 EP - 737 UR - http://dx.doi.org/10.1634/theoncologist.12-6-727 ER - TY - JOUR LB - 227. AU - Christodoulou, C AU - Dafni, U AU - Aravantinos, G AU - Koutras, A AU - Samantas, E AU - Karina, M TI - Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy J2 - Anticancer Res PY - 2009 VL - 29 SP - 693 EP - 702 ER - TY - JOUR LB - 228. AU - Engert, A AU - Josting, A AU - Haverkamp, H AU - Villalobos, M AU - Lohri, A AU - Sokler, M TI - Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial J2 - J Clin Oncol PY - 2010 VL - 28 SP - 2239 EP - 2245 UR - http://dx.doi.org/10.1200/JCO.2009.25.1835 ER - TY - JOUR LB - 229. AU - Fujisaka, Y AU - Sugiyama, T AU - Saito, H AU - Nagase, S AU - Kudoh, S AU - Endo, M TI - Randomised, Phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation J2 - Br J Cancer PY - 2011 VL - 105 SP - 1267 EP - 1272 UR - http://dx.doi.org/10.1038/bjc.2011.395 ER - TY - JOUR LB - 230. AU - Glaspy, J AU - Vadhan-Raj, S AU - Patel, R AU - Bosserman, L AU - Hu, E AU - Lloyd, RE TI - Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 study group trial J2 - J Clin Oncol PY - 2006 VL - 24 SP - 2290 EP - 2297 UR - http://dx.doi.org/10.1200/JCO.2005.03.8570 ER - TY - JOUR LB - 231. AU - Gupta, S AU - Singh, PK AU - Bisth, SS AU - Bhatt, ML AU - Pant, M AU - Gupta, R TI - Role of recombinant human erythropoietin in patients of advanced cervical cancer treated ‘by chemoradiotherapy.’ J2 - Cancer Biol Ther PY - 2009 VL - 8 SP - 13 EP - 17 UR - http://dx.doi.org/10.4161/cbt.8.1.7089 ER - TY - JOUR LB - 232. AU - Hernandez, E AU - Ganly, P AU - Charu, V AU - Dibenedetto, J AU - Tomita, D AU - Lillie, T TI - Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia J2 - Curr Med Res Opin PY - 2009 VL - 25 SP - 2109 EP - 2120 UR - http://dx.doi.org/10.1185/03007990903084164 ER - TY - JOUR LB - 233. AU - Leyland-Jones, B AU - Semiglazov, V AU - Pawlicki, M AU - Pienkowski, T AU - Tjulandin, S AU - Manikhas, G TI - Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study J2 - J Clin Oncol PY - 2005 VL - 23 SP - 5960 EP - 5972 UR - http://dx.doi.org/10.1200/JCO.2005.06.150 ER - TY - JOUR LB - 234. AU - Milroy, R AU - Bajetta, E AU - van den Berg, PM AU - O’Brien, MER AU - Perez-Manga, G AU - Georgoulias, V TI - Effects of epoetin alfa on anemia and patient-reported outcomes in patients with non-small cell lung cancer receiving chemotherapy: results of a European, multicenter, randomized, controlled study J2 - Eur J Clin Med Oncol PY - 2011 VL - 3 SP - 49 EP - 56 ER - TY - JOUR LB - 235. AU - Nagel, S AU - Kellner, O AU - Engel-Riedel, W AU - Guetz, S AU - Schumann, C AU - Gieseler, F TI - Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized Phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide J2 - Clin Lung Cancer PY - 2011 VL - 12 SP - 62 EP - 69 UR - http://dx.doi.org/10.3816/CLC.2011.n.009 ER - TY - JOUR LB - 236. AU - O’Shaughnessy, JA AU - Vukelja, SJ AU - Holmes, FA AU - Savin, M AU - Jones, M AU - Royall, D TI - Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy J2 - Clin Breast Cancer PY - 2005 VL - 5 SP - 439 EP - 446 UR - http://dx.doi.org/10.3816/CBC.2005.n.002 ER - TY - JOUR LB - 237. AU - Pirker, R AU - Ramlau, RA AU - Schuette, W AU - Zatloukal, P AU - Ferreira, I AU - Lillie, T TI - Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide J2 - J Clin Oncol PY - 2008 VL - 26 SP - 2342 EP - 2349 UR - http://dx.doi.org/10.1200/JCO.2007.15.0748 ER - TY - JOUR LB - 238. AU - Pronzato, P AU - Cortesi, E AU - van der Rijt, CC AU - Bols, A AU - Moreno-Nogueira, JA AU - de Oliveira, CF TI - Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial J2 - Oncologist PY - 2010 VL - 15 SP - 935 EP - 943 UR - http://dx.doi.org/10.1634/theoncologist.2009-0279 ER - TY - JOUR LB - 239. AU - Razzouk, BI AU - Hord, JD AU - Hockenberry, M AU - Hinds, PS AU - Feusner, J AU - Williams, D TI - Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy J2 - J Clin Oncol PY - 2006 VL - 24 SP - 3583 EP - 3589 UR - http://dx.doi.org/10.1200/JCO.2005.03.4371 ER - TY - JOUR LB - 240. AU - Reed, SD AU - Radeva, JI AU - Daniel, DB AU - Fastenau, JM AU - Williams, D AU - Schulman, KA TI - Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia J2 - Curr Med Res Opin PY - 2005 VL - 21 SP - 1527 EP - 1533 UR - http://dx.doi.org/10.1185/030079905X65394 ER - TY - JOUR LB - 241. AU - Waltzman, R AU - Croot, C AU - Justice, GR AU - Fesen, MR AU - Charu, V AU - Williams, D TI - Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy J2 - Oncologist PY - 2005 VL - 10 SP - 642 EP - 650 UR - http://dx.doi.org/10.1634/theoncologist.10-8-642 ER - TY - JOUR LB - 242. AU - Rosenzweig, MQ AU - Bender, CM AU - Lucke, JP AU - Yasko, JM AU - Brufsky, AM TI - The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events J2 - J Pain Symptom Manage PY - 2004 VL - 27 SP - 185 EP - 190 UR - http://dx.doi.org/10.1016/j.jpainsymman.2003.06.010 ER - TY - JOUR LB - 243. AU - Savonije, JH AU - van Groeningen, CJ AU - Wormhoudt, LW AU - Giaccone, G TI - Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data J2 - Oncologist PY - 2006 VL - 11 SP - 197 EP - 205 UR - http://dx.doi.org/10.1634/theoncologist.11-2-197 ER - TY - JOUR LB - 244. AU - Savonije, JH AU - van Groeningen, CJ AU - Wormhoudt, LW AU - Giaccone, G TI - Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level J2 - Oncologist PY - 2006 VL - 11 SP - 206 EP - 216 UR - http://dx.doi.org/10.1634/theoncologist.11-2-206 ER - TY - JOUR LB - 245. AU - Savonije, JH AU - van Groeningen, CJ AU - van Bochove, A AU - Honkoop, AH AU - van Felius, CL AU - Wormhoudt, LW TI - Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial J2 - Eur J Cancer PY - 2005 VL - 41 SP - 1560 EP - 1569 UR - http://dx.doi.org/10.1016/j.ejca.2005.03.024 ER - TY - JOUR LB - 246. AU - Schwartzberg, LS AU - Yee, LK AU - Senecal, FM AU - Charu, V AU - Tomita, D AU - Wallace, J TI - A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer J2 - Oncologist PY - 2004 VL - 9 SP - 696 EP - 707 UR - http://dx.doi.org/10.1634/theoncologist.9-6-696 ER - TY - JOUR LB - 247. AU - Senecal, FM AU - Yee, L AU - Gabrail, N AU - Charu, V AU - Tomita, D AU - Rossi, G TI - Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly J2 - Clin Breast Cancer PY - 2005 VL - 6 SP - 446 EP - 454 UR - http://dx.doi.org/10.3816/CBC.2005.n.050 ER - TY - JOUR LB - 248. AU - Thomas, G AU - Ali, S AU - Hoebers, FJ AU - Darcy, KM AU - Rodgers, WH AU - Patel, M TI - Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs. above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer J2 - Gynecol Oncol PY - 2008 VL - 108 SP - 317 EP - 325 UR - http://dx.doi.org/10.1016/j.ygyno.2007.10.011 ER - TY - JOUR LB - 249. AU - Tsuboi, M AU - Ezaki, K AU - Tobinai, K AU - Ohashi, Y AU - Saijo, N TI - Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study J2 - Jpn J Clin Oncol PY - 2009 VL - 39 SP - 163 EP - 168 UR - http://dx.doi.org/10.1093/jjco/hyn151 ER - TY - JOUR LB - 250. AU - Wilkinson, PM AU - Antonopoulos, M AU - Lahousen, M AU - Lind, M AU - Kosmidis, P TI - Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial J2 - Br J Cancer PY - 2006 VL - 94 SP - 947 EP - 954 UR - http://dx.doi.org/10.1038/sj.bjc.6603004 ER - TY - JOUR LB - 251. AU - Winquist, E AU - Julian, JA AU - Moore, MJ AU - Nabid, A AU - Sathya, J AU - Wood, L TI - Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia J2 - J Clin Oncol PY - 2009 VL - 27 SP - 644 EP - 646 UR - http://dx.doi.org/10.1200/JCO.2008.20.4966 ER - TY - JOUR LB - 252. AU - Strauss, HG AU - Haensgen, G AU - Dunst, J AU - Hayward, C AU - Koelbl, H TI - Effects of anaemia correction with epoetin beta in patients with advanced cervical cancer and radiochemotherapy J2 - J Clin Oncol PY - 2005 VL - 23 IS - Suppl. SP - 5121 ER - TY - JOUR LB - 253. AU - Delarue, R AU - Tilly, H AU - Mounier, N AU - Petrella, T AU - Salles, G AU - Thieblemont, C TI - Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial J2 - Lancet Oncol PY - 2013 VL - 14 SP - 525 EP - 533 UR - http://dx.doi.org/10.1016/S1470-2045(13)70122-0 ER - TY - JOUR LB - 254. AU - Boccia, R AU - Malik, IA AU - Raja, V AU - Kahanic, S AU - Liu, R AU - Lillie, T TI - Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia J2 - Oncologist PY - 2006 VL - 11 SP - 409 EP - 417 UR - http://dx.doi.org/10.1634/theoncologist.11-4-409 ER - TY - JOUR LB - 255. AU - Boccia, R AU - Lillie, T AU - Tomita, D AU - Balducci, L TI - The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia J2 - Oncologist PY - 2007 VL - 12 SP - 584 EP - 593 UR - http://dx.doi.org/10.1634/theoncologist.12-5-584 ER - TY - JOUR LB - 256. AU - Glaspy, J TI - Assessment of early and standard intervention with procrit® (epoetin alfa) 120,000 units once every three weeks (q3w) in patients with cancer receiving chemotherapy J2 - Blood PY - 2006 VL - 108 ER - TY - JOUR LB - 257. AU - Gregory, SA TI - Efficacy of darbepoetin alfa in the treatment of chemotherapy-induced anemia in non-Hodgkin’s lymphoma J2 - Support Cancer Ther PY - 2006 VL - 3 SP - 232 EP - 239 UR - http://dx.doi.org/10.3816/SCT.2006.n.021 ER - TY - JOUR LB - 258. AU - Gabrilove, JL AU - Perez, EA AU - Tomita, DK AU - Rossi, G AU - Cleeland, CS TI - Assessing symptom burden using the MD Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks J2 - Cancer PY - 2007 VL - 110 SP - 1629 EP - 1640 UR - http://dx.doi.org/10.1002/cncr.22943 ER - TY - JOUR LB - 259. AU - Larholt, K AU - Pashos, CL AU - Wang, Q AU - Bookhart, B AU - McKenzie, RS AU - Piech, CT TI - Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE): a registry for characterizing anaemia management and outcomes in oncology patients J2 - Clin Drug Investig PY - 2008 VL - 28 SP - 159 EP - 167 UR - http://dx.doi.org/10.2165/00044011-200828030-00003 ER - TY - CONF LB - 260. AU - Dammacco, F TI - A Placebo-Controlled Study on the Effect of Epoetin Alfa in Subjects with Multiple Myeloma Followed by an Open-Label Extension T2 - XIVth Meeting of the International Society of Haematology PY - 1997 SP - 49 ER - TY - JOUR LB - 261. AU - Dammacco, F TI - A placebo-controlled study on the effect of epoetin alfa in subjects with multiple myeloma followed by an open-label extension J2 - Eur J Cancer PY - 1997 VL - 33 IS - Suppl. 8 SP - 394 UR - http://dx.doi.org/10.1016/S0959-8049(97)84828-9 ER - TY - JOUR LB - 262. AU - Dammacco, F AU - Castoldi, G AU - Roedjer, S TI - A placebo-controlled study on the effect of epoetin alfa in subjects with multiple myeloma followed by an open-label extension J2 - Blood PY - 1997 VL - 90 IS - Suppl. 1 SP - 358a ER - TY - JOUR LB - 263. AU - Reddy, PK AU - Williams, D AU - Wilhelm, FE TI - An open-label pilot to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 units weekly followed by 60,000 units every 2 weeks J2 - Support Cancer Ther PY - 2006 VL - 4 SP - 56 EP - 62 UR - http://dx.doi.org/10.3816/SCT.2006.n.032 ER - TY - JOUR LB - 264. AU - Justice, G AU - Kessler, JF AU - Jadeja, J AU - Campos, L AU - Weick, J AU - Chen, CF TI - A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia J2 - Ann Oncol PY - 2005 VL - 16 SP - 1192 EP - 1198 UR - http://dx.doi.org/10.1093/annonc/mdi218 ER - TY - JOUR LB - 265. AU - Kotasek, D AU - Canon, JL AU - Mateos, MV AU - Hedenus, M AU - Rossi, G AU - Taylor, K TI - A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia J2 - Curr Med Res Opin PY - 2007 VL - 23 SP - 1387 EP - 1401 UR - http://dx.doi.org/10.1185/030079907X188053 ER - TY - JOUR LB - 266. AU - Glaspy, J AU - Vadhan-Raj, S AU - Patel, R AU - Bosserman, L AU - Hu, E AU - 20030125 Study Group Trial TI - Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial J2 - J Clin Oncol PY - 2006 VL - 24 SP - 2290 EP - 2297 UR - http://dx.doi.org/10.1200/JCO.2005.03.8570 ER - TY - JOUR LB - 267. AU - Montoya, VP AU - Xie, J AU - Williams, D AU - Woodman, RC AU - Wilhelm, FE TI - An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy J2 - Support Care Cancer PY - 2007 VL - 15 SP - 1385 EP - 1392 UR - http://dx.doi.org/10.1007/s00520-007-0263-6 ER - TY - JOUR LB - 268. AU - Charu, V AU - Saidman, B AU - Ben-Jacob, A AU - Justice, GR AU - Maniam, AS AU - Tomita, D TI - A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia J2 - Oncologist PY - 2007 VL - 12 SP - 1253 EP - 1263 UR - http://dx.doi.org/10.1634/theoncologist.12-10-1253 ER - TY - JOUR LB - 269. AU - Bastit, L AU - Vandebroek, A AU - Altintas, S AU - Gaede, B AU - Pintér, T AU - Suto, TS TI - Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia J2 - J Clin Oncol PY - 2008 VL - 26 SP - 1611 EP - 1618 UR - http://dx.doi.org/10.1200/JCO.2006.10.4620 ER - TY - JOUR LB - 270. AU - Gregory, SA AU - Williams, D TI - Epoetin alfa 60,000 U QW followed by Q2W maintenance dosing corrects anemia and maintains hemoglobin (Hb) in anemic patients with cancer receiving chemotherapy J2 - Blood PY - 2003 VL - 102 SP - 166b ER - TY - JOUR LB - 271. AU - Baltz, B AU - Gregory, SA AU - Ehmann, WC AU - Williams, D TI - Initial dosing of epoetin alfa 60,000 U qw followed by q2w maintenance for anemic patients with cancer receiving chemotherapy J2 - J Clin Oncol PY - 2004 VL - 22 IS - Suppl. 14 ER - TY - JOUR LB - 272. AU - Gregory, SA AU - Baltz, B AU - Williams, D TI - Every-two-week (Q2W) maintenance dosing with epoetin alfa in anemic patients with cancer receiving chemotherapy: 60,000 U qw to target Hb 12 g/dl, followed by 60,000 U q2w J2 - Blood PY - 2004 VL - 104 SP - 144b ER - TY - JOUR LB - 273. AU - Gregory, SA AU - Xie, J AU - Woodman, RC TI - Maintenance dosing with epoetin alfa every two weeks (q2w) in anemic patients with cancer receiving chemotherapy every one or four weeks: final results J2 - Blood PY - 2005 VL - 106 ER - TY - JOUR LB - 274. AU - Glaspy, JA AU - Charu, V AU - Luo, D AU - Moyo, V AU - Kamin, M AU - Wilhelm, FE TI - Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms J2 - Cancer PY - 2009 VL - 115 SP - 1121 EP - 1131 UR - http://dx.doi.org/10.1002/cncr.24127 ER - TY - JOUR LB - 275. AU - Steensma, DP AU - Molina, R AU - Sloan, JA AU - Nikcevich, DA AU - Schaefer, PL AU - Rowland, KM, Jr TI - Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer J2 - J Clin Oncol PY - 2006 VL - 24 SP - 1079 EP - 1089 UR - http://dx.doi.org/10.1200/JCO.2005.02.7276 ER - TY - JOUR LB - 276. AU - Steensma, DP AU - Molina, R AU - Sloan, JA AU - Nikcevich, DA AU - Schaefer, PL AU - Roland, KM, Jr TI - A Phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) study N02C2 J2 - J Clin Oncol PY - 2005 VL - 23 IS - Suppl. 16 SP - A-8031 ER - TY - JOUR LB - 277. AU - Straus, DJ AU - Testa, MA AU - Sarokhan, BJ AU - Czuczman, MS AU - Tulpule, A AU - Turner, RR TI - Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies J2 - Cancer PY - 2006 VL - 107 SP - 1909 EP - 1917 UR - http://dx.doi.org/10.1002/cncr.22221 ER - TY - JOUR LB - 278. AU - Glaspy, J AU - Henry, D AU - Patel, R AU - Tchekmedyian, S AU - Applebaum, S AU - Berdeaux, D TI - Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa J2 - Eur J Cancer PY - 2005 VL - 41 SP - 1140 EP - 1149 UR - http://dx.doi.org/10.1016/j.ejca.2005.01.021 ER - TY - JOUR LB - 279. AU - Gordon, D AU - Nichols, G AU - Ben-Jacob, A AU - Tomita, D AU - Lillie, T AU - Miller, C TI - Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study J2 - Oncologist PY - 2008 VL - 13 SP - 715 EP - 724 UR - http://dx.doi.org/10.1634/theoncologist.2007-0241 ER - TY - JOUR LB - 280. AU - Canon, JL AU - Vansteenkiste, J AU - Bodoky, G AU - Mateos, MV AU - Bastit, L AU - Ferreira, I TI - Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia J2 - J Natl Cancer Inst PY - 2006 VL - 98 SP - 273 EP - 284 UR - http://dx.doi.org/10.1093/jnci/djj053 ER - TY - JOUR LB - 281. AU - Canon, JL AU - Vansteenkiste, J AU - Hedenus, M AU - Gascon, P AU - Bokemeyer, C AU - Ludwig, H TI - Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of < 9 g/dl versus 9 to < 10 g/dl versus ≥ 10 g/dl: an exploratory analysis of a phase 3 trial J2 - Med Oncol PY - 2012 VL - 29 SP - 2291 EP - 2299 UR - http://dx.doi.org/10.1007/s12032-011-0103-x ER - TY - JOUR LB - 282. AU - Vansteenkiste, J AU - Hedenus, M AU - Gascon, P AU - Bokemeyer, C AU - Ludwig, H AU - Vermorken, J TI - Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dl versus > or = 10 g/dl: an exploratory analysis from a randomized, double-blind, active-controlled trial J2 - BMC Cancer PY - 2009 VL - 9 SP - 311 UR - http://dx.doi.org/10.1186/1471-2407-9-311 ER - TY - JOUR LB - 283. AU - Schwartzberg, L AU - Burkes, R AU - Mirtsching, B AU - Rearden, T AU - Silberstein, P AU - Yee, L TI - Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial J2 - BMC Cancer PY - 2010 VL - 10 SP - 581 UR - http://dx.doi.org/10.1186/1471-2407-10-581 ER - TY - JOUR LB - 284. AU - Schouwink, JH AU - Codrington, H AU - Sleeboom, HP AU - Kerkhofs, LG AU - Wormhoudt, LW TI - Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy J2 - Eur J Cancer PY - 2008 VL - 44 SP - 819 EP - 829 UR - http://dx.doi.org/10.1016/j.ejca.2008.02.017 ER - TY - JOUR LB - 285. AU - Cella, DF AU - Tulsky, DS AU - Gray, G AU - Sarafian, B AU - Linn, E AU - Bonomi, A TI - The Functional Assessment of Cancer Therapy scale: development and validation of the general measure J2 - J Clin Oncol PY - 1993 VL - 11 SP - 570 EP - 579 ER - TY - JOUR LB - 286. AU - Ware, JE, Jr AU - Sherbourne, CD TI - The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection J2 - Med Care PY - 1992 VL - 30 SP - 473 EP - 483 UR - http://dx.doi.org/10.1097/00005650-199206000-00002 ER - TY - JOUR LB - 287. AU - Hunt, SM AU - McEwen, J AU - McKenna, SP TI - Measuring health status: a new tool for clinicians and epidemiologists J2 - J R Coll Gen Pract PY - 1985 VL - 35 SP - 185 EP - 188 ER - TY - BOOK LB - 288. AU - Bowling, A TI - Measuring Health, A Guide to Rating Scales and Questionnaires CY - Buckingham PB - Oxford University Press PY - 1997 ER - TY - JOUR LB - 289. AU - Bretscher, M AU - Rummans, T AU - Sloan, J AU - Kaur, J AU - Bartlett, A AU - Borkenhagen, L TI - Quality of life in hospice patients. A pilot study J2 - Psychosomatics PY - 1999 VL - 40 SP - 309 EP - 313 UR - http://dx.doi.org/10.1016/S0033-3182(99)71224-7 ER - TY - JOUR LB - 290. AU - Sloan, JA AU - Loprinzi, CL AU - Kuross, SA AU - Miser, AW AU - O’Fallon, JR AU - Mahoney, MR TI - Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer J2 - J Clin Oncol PY - 1998 VL - 16 SP - 3662 EP - 3673 ER - TY - JOUR LB - 291. AU - Derogatis, LR AU - Melisaratos, N TI - The Brief Symptom Inventory: an introductory report J2 - Psychol Med PY - 1983 VL - 13 SP - 595 EP - 605 UR - http://dx.doi.org/10.1017/S0033291700048017 ER - TY - JOUR LB - 292. AU - Morasso, G AU - Costantini, M AU - Baracco, G AU - Borreani, C AU - Capelli, M TI - Assessing psychological distress in cancer patients: validation of a self-administered questionnaire J2 - Oncology PY - 1996 VL - 53 SP - 295 EP - 302 UR - http://dx.doi.org/10.1159/000227576 ER - TY - JOUR LB - 293. AU - de Haes, J AU - Curran, D AU - Young, T AU - Bottomley, A AU - Flechtner, H AU - Aaronson, N TI - Quality of life evaluation in oncological clinical trials – the EORTC model. The EORTC Quality of Life Study Group J2 - Eur J Cancer PY - 2000 VL - 36 SP - 821 EP - 825 UR - http://dx.doi.org/10.1016/S0959-8049(00)00007-1 ER - TY - JOUR LB - 294. AU - Michallet, M AU - Goldet, K AU - Sobh, M AU - Morisset, S AU - Chelghoum, Y AU - Thomas, X TI - Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients J2 - Cancer PY - 2013 VL - 119 SP - 107 EP - 114 UR - http://dx.doi.org/10.1002/cncr.27686 ER -